Severe Kidney Disease and the Choice Between Two MET Inhibitors
A newly diagnosed MET exon 14 skipping lung cancer in a patient whose kidney function sits below where either pivotal trial reliably studied its drug. The disagreement is less about which drug works better and more about which unknown is easier to manage safely.
Dolores V., 76, has lived alone in the same house for the eleven years since her husband died, and manages the details of that independence deliberately — a labeled pillbox refilled every Sunday, a magnifier kept by the kitchen table for the macular degeneration that has left her legally blind in her left eye. A cough that would not resolve after a presumed pneumonia led to a chest CT, then a biopsy of a right lower lobe mass showing a sarcomatoid component and a MET exon 14 skipping mutation on tissue testing — an alteration disproportionately found in older patients and in tumors with exactly this histology. Her kidney disease is longstanding and stable, attributed to decades of hypertension, with a baseline eGFR of 24 that has not required dialysis and is not expected to progress quickly; her nephrologist, following her twice yearly for years, has never seen it move more than a point or two off that number regardless of season or minor illness.
Both drugs approved for this mutation, capmatinib and tepotinib, reached approval through trials — GEOMETRY mono-1 and VISION — that each excluded or enrolled vanishingly few patients anywhere near her level of kidney function; the labeled dosing for both rests on pharmacokinetic data gathered almost entirely in patients with much better-preserved renal function than hers. Both drugs are also associated, at meaningful rates in each trial, with peripheral edema, a class effect of MET inhibition itself rather than a quirk of either specific molecule — a finding that will be harder to read cleanly against her existing baseline of mild venous-insufficiency swelling than it would be against a normal pair of legs. That leaves the real decision resting less on which drug’s trial produced the better headline response rate and more on which drug’s unstudied territory is easier to manage safely in a woman who will be taking it, unsupervised, in her own kitchen, with a pillbox she fills once a week by feel and memory as much as by sight.
Choosing between two drugs neither trial studied at her kidney function
Start capmatinib. GEOMETRY mono-1 is the larger, more mature dataset for this mutation, with a meaningful overall response rate and real intracranial activity in the subset who had brain metastases at baseline — not her situation today, but reassuring background if it becomes one. Neither trial adequately studied kidney function this low, so in the absence of a clear renal signal favoring either drug, I would rather start with the one backed by more total patient experience.
The size of the trial dataset is a real point, and I am not disputing that GEOMETRY mono-1 enrolled more patients.
But more total experience is not the same as more relevant experience for a woman managing her own once-a-week pillbox with a magnifier. Capmatinib is 400mg twice daily — two 200mg tablets, morning and evening, four tablets across the day on two separate schedules. Tepotinib is 450mg once daily, two 225mg tablets taken together, one event in her day instead of two. The tablet counts are closer than they sound — four a day against two — but the number of separate dosing events is not, and for a patient whose actual risk isn’t a marginal difference in response rate but a missed or doubled dose from confusing an evening dose with a morning one, collapsing two daily schedules into one is the more clinically meaningful choice, not a convenience footnote.
Neither of you is wrong about what you are each weighting, but neither trial’s dosing algorithm was built for an eGFR of 24, and that gap does not close no matter which drug we pick. Whatever we start, she needs closer-than-standard monitoring — earlier and more frequent labs for hepatotoxicity, and an explicit early check for peripheral edema, which both drugs cause at meaningful rates and which is genuinely harder to distinguish early from her existing venous changes.
If simplicity of the regimen is going to be the deciding factor given her situation, let it decide — but let’s not call either drug’s safety margin at her renal function well-established just because we’ve made a reasonable choice between them.
Agreed: start tepotinib given the adherence advantage of a single once-daily dosing event for her specific living situation, with baseline and two-week comprehensive metabolic and liver panels, and an early home-health check for new or worsening lower-extremity edema against her existing baseline.
Not agreed: the Medical Oncologist accepted the adherence argument as decisive for Dolores specifically, but asked that it be recorded that capmatinib remains at least as reasonable a first choice in a patient without her particular adherence profile — not to be generalized into a standing preference for tepotinib going forward.